The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | A retrospective study of venetoclax re-treatment in CLL patients
Meghan Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a retrospective study of venetoclax re-treatment for chronic lymphocytic leukemia (CLL) patients following progression or relapse after an initial venetoclax-based regimen. A cohort of patients with history of previous CLL treatment, including those previously treated with BTK inhibitors, was identified and their overall response rate to venetoclax re-treatment was found to be 72.2%. This line of treatment was also found to have an encouraging safety profile, suggesting it may be a viable option for CLL patients requiring further therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Curio Science
